MedTrace Logo

Metabolites of Tramadol in the Postoperative Surgical Patients

NCT04004481 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-07-09

Study results available
· View outcomes & findings →

Summary

Tramadol is opioid analgesic widely used to treat moderate to severe pain. It is metabolized by cytochrome CYP2D6 into two major metabolites: pharmacologically active metabolite O-desmethyltramadol (M1) and inactive N-desmethyltramadol (M2), respectively. Tramadol kinetics in a population of patients undergoing major abdominal surgical procedures, and in patients with a greater or lesser degree of organic failure, is still not well researched. The investigators will measure plasma concentrations of tramadol and its metabolites after usual tramadol doses in ICU patients after major abdominal surgery. Also analgesic affect and side effect of tramadol will be recorded.

Conditions

Interventions

DRUG

Postoperative analgesia using tramadol

Tramadol 100 mg will be given to the patients in the postoperative period.

Sponsors & Collaborators

  • Josip Juraj Strossmayer University of Osijek

    collaborator OTHER

  • Osijek University Hospital

    lead OTHER

Principal Investigators

  • Nenad Neskovic, MD · Osijek University Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2020-02-28
Completion
2020-03-13

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004481 on ClinicalTrials.gov